Literature DB >> 8866767

Dosing issues and depot medication in the maintenance treatment of schizophrenia.

J M Kane1.   

Abstract

Antipsychotic medication has proved to be of enormous value in the long-term treatment of schizophrenia. Maintenance medication has been shown to reduce rates of relapse and rehospitalization substantially and to enable patients to benefit from psychosocial treatments and vocational rehabilitation. At the same time, improving compliance while optimizing the benefits and minimizing the risks associated with long-term drug treatment has been a major challenge. Depot medications are a valuable part of a maintenance strategy for many patients. Considerable data are now available on dose-response relationships with depot drugs, improving our ability to use them judiciously.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8866767

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  7 in total

1.  The visual search analogue of latent inhibition: implications for theories of irrelevant stimulus processing in normal and schizophrenic groups.

Authors:  R E Lubow; Oren Kaplan
Journal:  Psychon Bull Rev       Date:  2005-04

2.  A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia.

Authors:  Wayne Macfadden; Yi-Wen Ma; J Thomas Haskins; Cynthia A Bossie; Larry Alphs
Journal:  Psychiatry (Edgmont)       Date:  2010-11

Review 3.  Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.

Authors:  A Cario Altamura; Francesca Sassella; Annalisa Santini; Clauno Montresor; Sara Fumagalli; Emanuela Mundo
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Authors:  Prakash S Masand; Sanjay Gupta
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 5.  Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.

Authors:  Hans-Jürgen Möller
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms.

Authors:  Wayne Macfadden; Caleb M Adler; Ibrahim Turkoz; John T Haskins; Norris Turner; Larry Alphs
Journal:  BMC Psychiatry       Date:  2011-10-28       Impact factor: 3.630

7.  Achieving stable remission with maintenance electroconvulsive therapy in a patient with treatment-resistant schizophrenia: A case report.

Authors:  Sebastian Moeller; Neele Kalkwarf; Caroline Lücke; Diana Ortiz; Sonja Jahn; Christiane Först; Niclas Braun; Alexandra Philipsen; Helge H O Müller
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.